Ipsen (CHIX:IPNP) Policy Acquisition Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IPNP Ipsen SA CHIX:IPNP
94 GF Score
Price €166.25
GF Value €143.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipsen Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

CHIX:IPNP
94GF Score
Ipsen SA CHIX:IPNP
Policy Acquisition Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (CHIX:IPNP) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €166.25 is trading 16% above its estimated GF Value™ of €143.32. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for CHIX:IPNP:

  • Policy Acquisition Expense:
  • GF Value™: €143.32 vs. price of €166.25 (16% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the CHIX:IPNP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for CHIX:IPNP

Policy Acquisition Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€166.25
Price
€143.32
GF Value